Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138603 · ClinicalTrials.gov registry record · Phase 3
Metoprolol to Reduce Perioperative Myocardial Injury
A Phase 3 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT03138603 is a Phase 3 study that has completed, run by University of Chicago. The registered enrollment target is 72 participants.
The verdict
NCT03138603, a Phase 3 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this research study is to test if a commonly used, FDA-approved medication, called metoprolol, given at the conclusion of anesthesia following surgery, and during postoperative admission, reduces the possibility of heart related complications in patients with coronary artery disease (CAD).
Interventions
- DRUG Placebo
- DRUG Metoprolol Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-12 |
| Est. Completion | 2023-08-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138603
The ClinicalTrials.gov registry entry for NCT03138603 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03138603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138603 about?
NCT03138603 is a clinical study titled "Metoprolol to Reduce Perioperative Myocardial Injury". The purpose of this research study is to test if a commonly used, FDA-approved medication, called metoprolol, given at the conclusion of anesthesia following surgery, and during postoperative admission, reduces the possibility of heart related complications in patients with coronary artery disease (...
What is the current status of trial NCT03138603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2016-12. Estimated completion is 2023-08-29.
What interventions are being tested in trial NCT03138603?
The interventions under investigation include: Placebo (DRUG), Metoprolol Tartrate (DRUG).
Who is sponsoring clinical trial NCT03138603?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.